Citi Starts ArriVent BioPharma (AVBP) at Buy, 'Leader of the PACC in the EGFR Exon 20 TKI Race'

February 20, 2024 3:07 AM EST Send to a Friend
(Updated - February 20, 2024 3:54 AM EST)

Citi analyst Yigal Nochomovitz initiates coverage on ArriVent BioPharma (NASDAQ: AVBP) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login